Discover 1,191 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,191
Active & Responsive
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
for
Atoptic Dermatitis
Location: 20 recruiting locations
Sponsor: Evommune, Inc.
Sex: All
Age: 18+
Code: NCT07150845
Phase2, Recruiting
Active & Responsive
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
for
Psoriasis, Overweight or Obesity
Location: 42 recruiting locations
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06857942
Recruiting
Active & Responsive
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
for
Treatment Resistant Depression
Location: 51 recruiting locations
Sponsor: LivaNova
Sex: All
Age: 18+
Code: NCT03887715
Recruiting
Active & Responsive
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
for
Progressive Pulmonary Fibrosis
Location: 56 recruiting locations
Sponsor: Avalyn Pharma Inc.
Sex: All
Age: 18+
Code: NCT06329401
Phase2, Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
for
NASH - Nonalcoholic Steatohepatitis,
Location: 133 recruiting locations
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06528314
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
for
NASH With Fibrosis, MASH With Fibrosis
Location: 143 recruiting locations
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06215716
Phase3, Recruiting
Active & Responsive
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: 21 recruiting locations
Sponsor: IDEAYA Biosciences
Sex: All
Age: 18+
Code: NCT05787587
Phase1, Recruiting
Active & Responsive
A Study of RSLV-132 in Females With Sjögren's Disease
for
Primary Sjögren Syndrome
Location: 23 recruiting locations
Sponsor: Resolve Therapeutics
Sex: Female
Age: 18 - 70+
Code: NCT06440525
Phase2, Recruiting
Active & Responsive
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
for
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Location: 90 recruiting locations
Sponsor: Cleerly, Inc.
Sex: All
Age: 55+
Code: NCT06112418
Recruiting
Active & Responsive
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer